A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations. - Balasundaram A; Doss GPC (Frontiers in molecular biosciences, 2024)